Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.78−0.08 (-4.30%)
Close on Nov 17, 2026Market cap $58.25MP/E –Yield –
Insight Molecular Diagnostics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Insight Molecular Diagnostics's price to book ratio was 156.6× on Oct 31, 2025, against 2.2× a year earlier. Over the last 5 years it ranged from 0.4× to 156.6×, with a median of 2.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Oct 31, 2025 | 156.6× | +153.4 |
| 2024 | Dec 31, 2024 | 3.3× | +2.7 |
| 2023 | Dec 29, 2023 | 0.6× | +0.1 |
| 2022 | Dec 30, 2022 | 0.5× | −1.5 |
| 2021 | Dec 31, 2021 | 2.0× | −2.6 |
| 2020 | Dec 31, 2020 | 4.6× | +0.7 |
| 2019 | Dec 31, 2019 | 4.0× | −3.5 |
| 2018 | Dec 31, 2018 | 7.5× | −10.7 |
| 2017 | Dec 29, 2017 | 18.2× | +2.2 |
| 2016 | Dec 30, 2016 | 15.9× | – |
See a number that looks wrong?